Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy in advanced squamous NSCLC
NCT03668496Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the lung (SCCL) comparing SHR-1210 + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoint: Progression-Free Survival up to 24 month. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03668496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668496.